Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
A 2-month interruption of only nonnucleoside reverse transcriptase inhibitors (NNRTIs) for patients carrying mutations associated with resistance to NNRTIs was followed by no change in either viral load or CD4 cell counts. These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases.
Wirden
Marc
M
Department of Virology, Pitié-Salpêtrière Hospital. Department of Pharmacology, Bichat Hospital, Paris, France.
Simon
Anne
A
Schneider
Luminita
L
Tubiana
Roland
R
Paris
Luc
L
Marcelin
Anne Genevieve
AG
Delaugerre
Constance
C
Legrand
Mayeule
M
Herson
Serge
S
Peytavin
Gilles
G
Katlama
Christine
C
Calvez
Vincent
V
D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral / Q000235:genetics*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000187:drug effects / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D009154:Mutation; D019829:Nevirapine / Q000008:administration & dosage / Q000494:pharmacology; D010078:Oxazines / Q000008:administration & dosage / Q000494:pharmacology; D012367:RNA, Viral / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D019562:Viral Load
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D054303:HIV Reverse Transcriptase; C098320:efavirenz